Correspondence | Published:

Challenges in the gene therapy commercial ecosystem

Nature Biotechnology volume 35, pages 813815 (2017) | Download Citation

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. 1.

    , & Nat. Rev. Genet. 4, 346–358 (2003).

  2. 2.

    , , & Nat. Biotechnol. 23, 1073–1078 (2005).

  3. 3.

    Hum. Gene Ther. 23, 1–3 (2012).

  4. 4.

    & Acad. Manage. J. 58, 1180–1207 (2015).

  5. 5.

    & Nat. Biotechnol. 32, 874–876 (2014).

Download references

Author information


  1. The Wharton School, University of Pennsylvania, Philadelphia, Pennsylvania, USA.

    • Rahul Kapoor
  2. IESE Business School, Barcelona, Spain.

    • Thomas Klueter
  3. Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.

    • James M Wilson


  1. Search for Rahul Kapoor in:

  2. Search for Thomas Klueter in:

  3. Search for James M Wilson in:

Competing interests

J.M.W. is an advisor to REGENXBIO, Dimension Therapeutics and Solid Gene Therapy, and is a founder of, holds equity in, and has a sponsored research agreement with REGENXBIO and Dimension Therapeutics. In addition, he is a consultant to several biopharmaceutical companies and is an inventor on patents licensed to various biopharmaceutical companies.

Corresponding author

Correspondence to Rahul Kapoor.

About this article

Publication history



Newsletter Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing